The Long Wait for the Cancer Breakthrough Could Soon Be Over
After the challenging transition phase of the last two years, the company now needs to prove that the new vaccines for RSV and respiratory combinations can sustainably close the revenue gap.
Reading Time: 2 minutes
It is January 2026, and a glance at Moderna's stock price shows that the "Long Covid" effect on the market is still ongoing. The stock is trading far from its former highs. The last two years have indeed been a tough transition phase, as management predicted. The RSV vaccine approved in 2024 (mRESVIA) is generating revenue, but it faces fierce competition and has not been able to fill the huge revenue gaps of the pandemic era alone, as expected. Why could entering now, at the beginning of 2026, still be interesting? Because the phase of "hope" is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
